International field testing of the reliability and validity of the EORTC QLQ‐BM22 module to assess health‐related quality of life in patients with bone metastases
Authors:
- Edward ChowECEdward Chow
- Janet NguyenJNJanet Nguyen
- Ming‐Feng HouMHMing‐Feng Hou
- Alysa FairchildAFAlysa Fairchild
- Wei‐Chu ChieWCWei‐Chu Chie
Open Access
Abstract
BACKGROUND: The objective of this international field study was to test the reliability, validity, and responsiveness of the European Organization for Research and Treatment of Cancer (EORTC) QLQ‐BM22 module to assess health‐related quality of life (HRQOL) in patients with bone metastases.METHODS: Patients undergoing a variety of bone metastases‐specific treatments were accrued. The QLQ‐BM22 was administered with the QLQ‐C30 at baseline and at 1 follow‐up time point internationally. A debriefing questionnaire was administered to determine patient acceptability and understanding.RESULTS: Large‐scale field testing of the QLQ‐BM22 in addition to the QLQ‐C30 took place in 7 countries: Brazil, Canada, Cyprus, Egypt, France, India, and Taiwan. A total of 400 patients participated. Multitrait scaling analyses confirmed 4 scales in the 22‐item module. The scales were able to discriminate between clinically distinct patient groups, such as between those with a poor and those with a better performance status. The QLQ‐BM22 was well received in all 7 countries, and the majority of patients did not recommend any significant changes from the module in its current form.CONCLUSIONS: The final QLQ‐BM22 module contains 22 items and 4 scales assessing Painful Sites, Painful Characteristics, Functional Interference, and Psychosocial Aspects. Results confirmed the validity, reliability, cross‐cultural applicability, and sensitivity of the 22‐item EORTC QLQ‐BM22. It is therefore recommended that the QLQ‐BM22 be used in addition to the QLQ‐C30 in clinical trials to assess HRQOL in patients with bone metastases. Cancer 2012;. © 2011 American Cancer Society.Keywords
This publication has 8 references indexed in Scilit:
- Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)European Journal of Cancer, 2011
- Switching Breast Cancer Patients with Progressive Bone Metastases to Third-Generation Bisphosphonates: Measuring Impact Using the Functional Assessment of Cancer Therapy-Bone PainJournal of Pain and Symptom Management, 2009
- The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22European Journal of Cancer, 2009
- An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myelomaEuropean Journal of Cancer, 2007
- International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastasesRadiotherapy and Oncology, 2002
- Metastasis to bone: causes, consequences and therapeutic opportunitiesNature Reviews Cancer, 2002
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- Incidence, prevalence and distribution of bone metastasesBone, 1991